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ABSTRAK 
 
Tajuk: Membandingkan dua jenis dos intravena granisetron yang berbeza dengan intravena 
pethidine untuk mengelakkan mengigil selepas pembiusan spinal. 
Later Belakang: Mengigil selepas pembiusan adalah keadaan yang stress kepada fisologi 
dan psikologi. Walaupun pethidine merupakan pilihan pertama terapi, ia membawa kesan 
sampingan seperti mengantuk, loya dan muntah. Intravena (IV) granisetron dengan dos 40 
mcg/kg telah dibuktikan dalam kajian sebelum ini dapat mengelakkan komplikasi mengigil 
selepas pembiusan. Sekarang, tiada kajian menunjukkan dos minimal granisetron dapat 
mengelakkan mengigil selepas pembiusan spinal. Kajian ini adalah untuk membandingkan 
dua dos granisetron yang berbeza dengan pethidine yang dapat mengelakkan mengigil 
selepas pembiusan.  
Metodologi: Ini merupakan kajian prospektif rawak plasebo rabun dua pihak. Seramai 96 
pesakit dalam kumpulan ASA I dan II, berumur dalam lingkungan 18 hingga 65 tahun 
menjalani pembedahan ortopedik anggota kaki melalui pembiusan spinal telah dikaji. Pesakit 
secara rawak dipilih untuk menerima samada suntikan intravena (IV) granisetron 10 mcg/kg 
(Kumpulan 1), IV granisetron 40 mcg/kg (Kumpulan 2) atau IV pethidine 0.4 mg/kg 
(Kumpulan 3) sebelum suntikan “intrathecal” dengan menggunakan 15mg hyperbaric 
bupivacaine 0.5%. Insiden dan tahap mengigil telah direkodkan.  
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Keputusan: Secara keseluruhan, kejadian menggigil semasa pembiusan spinal dalam kajian 
kami adalah tidak signifikan antara 3 kumpulan (p = 0.404).  Manakala, IV pethidine adalah 
lebih cenderung mengakibatkan kesan mengantuk berbanding dengan granisetron (p < 0.001).  
Kesimpulan: IV granisetron 10 mcg/kg mempunyai efikasi yang sama apabila dibandingkan 
dengan IV granisetron 40 mcg/kg dan IV pethidine 0.4 mg/kg dalam mencegah kejadian 
gigilan ketika pembiusan spina untuk pembedahan ortopedik anggota kaki.  
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ABSTRACT 
 
Title: Comparing two different doses of intravenous granisetron versus intravenous pethidine 
for prevention of shivering in patients undergoing spinal anaesthesia 
Background: Post-anaesthesia shivering is physiologically and psychologically stressful 
event. Pethidine, which is commonly recognised as first-line therapy, can have several side 
effects such as sedative effects, nausea and vomiting. Granisetron has been proven in various 
studies for prevention of post-anaesthesia shivering at 40mcg/kg intravenously. To date, no 
study has demonstrated the minimum dose of granisetron to prevent post-anaesthesia 
shivering. This study compared two different dosages of intravenous granisetron versus 
pethidine for prevention of post-anaesthesia shivering.  
Methods: This was a prospective, randomized, double-blinded study. A total of 96 patients 
with ASA classification I and II, aged between 18 and 65 years old scheduled for orthopaedic 
lower limb surgery under spinal anaesthesia were recruited. Patients were randomly allocated 
to receive either intravenous (IV) granisetron 10mcg/kg (Group 1), IV granisetron 40mcg/kg 
(Group 2) or IV pethidine 0.4mg/kg (Group 3) before an intrathecal injection of 15 mg 0.5% 
hyperbaric bupivacaine. The incidence and severity of shivering with side effects of tested 
drugs were recorded.  
Results: The incidence of shivering associated with spinal anaesthesia in our study was not 
significant different amongst the 3 groups (p = 0.404). However, pethidine was associated 
with sedative effects when compared with granisetron (p < 0.001).  
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Conclusions: IV granisetron at 10mcg/kg had similar efficacy when compared to both IV 
granisetron 40mcg/kg and IV pethidine 0.4mg/kg in preventing shivering during spinal 
anaesthesia for orthopaedic lower limb surgery. 
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ABBREVIATIONS 
 
 
5-HT Serotonin or 5-Hydroxytrptamine 
5-HT3 5-Hydroxytryptamine type 3 
ANOVA Analysis of Variance 
BMI Body Mass Index 
BP Blood Pressure 
ECG Electrocardiogram 
PGH Penang General Hospital 
HUSM Hospital Universiti Sains Malaysia 
HR Heart Rate 
ISMP Institute for Safe Medication Practices 
IV  Intravenous or Intravena (Malay language)  
 
NIBP Non-invasive Blood Pressure 
SBP Systolic Blood Pressure 
SpO2 Oxygen Saturation 
SPSS Statistical Package for the Social Science 
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1.1 INTRODUCTION 
Perioperative shivering is one of the common distressing events encountered 
during our daily anaesthesia practice. Its incidence is estimated ranging from 6 – 60% 
after spinal anaesthesia(1). Shivering is physiologically and psychologically stressful to 
both patients and attending anaesthetist. Apart from interfering vital signs monitoring 
secondary to motion artefacts, it can increase risk of myocardium ischaemia in those with 
limited reserve, increase carbon dioxide production, increase metabolic oxygen 
consumption and thus hypoxia, increase respiratory workload with raise minute 
ventilation and cause unpleasant experiences in operation theatre.  
Thus, various pharmacological and non-pharmacological methods have been 
attempted for preventing and treating post-anaesthesia shivering. One of the most 
common physical methods is surface warming. However, it is considered not to be as 
useful as drugs for this purpose because the skin surface contributes to only 20% of 
shivering control. Moreover, it can be useful only during slight hypothermia with core 
temperature > 35°C (2). On the other hand, various drugs have been studied and used to 
prevent post-anaesthesia shivering, but none of these drugs have received universal 
acceptance (3). Different problems and side effects are associated with these drugs. For 
example, tramadol is known to cause nausea and vomiting. Pethidine is associated with 
bradycardia, nausea and vomiting, sedative effects, respiratory depression and 
haemodynamic changes. Sedative effects of ketamine (4) can be dangerous to elderly 
populations.  
Recently, granisetron, a specific 5-HT3 receptor antagonist, at a dose of 40mcg/kg, 
has been found to be effective in reducing the incidence of post- anaesthesia shivering in 
some studies. The mechanism of action of granisetron anti-shivering effect could be 
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related to the inhibition of serotonin reuptake on the pre-optic anterior hypothalamic 
region (4). Serotonin (5-hydroxytryptamine [5-HT]) is a biological amine that acts as a 
neurotransmitter in the brain and the spinal cord. Studies suggest that the serotoninergic 
system has a role in the control of post-anaesthesia shivering. The 5-HT3 receptor 
antagonist inhibits the uptake of serotonin in the pre-optic anterior hypothalamic region, 
which influences both heat production and heat loss (4). In animal models, direct 
intraventricular injection of serotonin influences body temperature and shivering (2). 
Granisetron is currently registered in the Ministry of Health Drug Formulary, 2013, at a 
dose of 10-40mcg/kg in children over 2 years old or at a dose of 1 – 3 mg in an adult as 
intravenous (IV) bolus for prevention of nausea and vomiting associated with 
chemotherapy and radiotherapy. It is easily available in Malaysia government hospital 
and routinely used for prevention of post-operative nausea and vomiting in anaesthesia 
service.  It gains its popularity with relative safer profile as compared to other anti-emetic 
medications. For the purpose of prevention post-anaesthesia shivering, IV granisetron 40 
mcg/kg is recommended in most studies. Iqbal et al. (5) showed that the IV granisetron 
(at dose of 40mcg/kg) is equally effective with  IV pethidine (25mg) in preventing post-
operative shivering compared to negative control group (saline group). The incidences of 
shivering among 3 groups of subjects in their study were reported as below: Group 
Pethidine (7%) and Group Granisetron (17%) and Group Saline (60%), with p<0.05. 
Another study by Sajedi et al. (6) in year 2008 found that the prophylactic used of 
granisetron at 40mcg/kg was as effective as pethidine 0.4mg/kg or tramadol 0.1mg/kg in 
preventing post-anaesthesia shivering in a group of patients undergoing elective 
orthopaedic lower limb surgery under general anaesthesia. Teoh et al.(7) showed that at 
this 40mcg/kg, granisetron had a similar efficacy with IV Ketamine 0.25mg/kg in 
prevention of shivering during spinal anaesthesia for elective orthopaedic lower limb 
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surgery in a group of 90 subjects in Malaysia. They showed that the incidence of shivering 
was significantly higher in control group (i.e. normal saline), which is 43.3% compared 
to granisetron group with incidence of 10%. A.A. Eldaba and Y.M. Amr in 2012 (8) 
compared IV granisetron 10mcg/kg versus IV normal saline in a group of 80 children age 
2 – 5 year old who underwent spinal anaesthesia for lower limb surgery. They found that 
IV granisetron 10mcg/kg was effective in preventing post-spinal shivering. 
Pethidine is one of the common drug used to treat post anaesthesia shivering. It 
has been extensively evaluated and is widely recognized as the first line therapy for peri-
operative shivering (9). The mechanism of action of pethidine in the treatment of post-
anaesthesia shivering is not completely understood. The site of action is most probably 
either the thermoregulatory center or the opioid receptor. It is suggested that pethidine 
acts via k- rather than μ-opioid receptors to prevent shivering.  The anti-shivering action 
of pethidine can be inhibited by high dose naloxone, which blocks both μ and k receptors, 
but not by low dose of naloxone which only block μ receptors (5). In a meta-analysis over 
20 trials by Peter Kranke et al. (10) in year 2002,  it is reported that the side effects of 
pethidine could be nausea and vomiting (7.3%), respiratory depression (4.2%). Therefore, 
the use of pethidine can be limited by its side effects profile, which also include delayed 
gastric emptying and prolong length of recovery stay. These can increase the overall cost 
of treatment.  
At the sametime, Sajedi et al. (6) suggested limitations use of opoids in their study 
were risk of respiratory depression, sedation, nausea and vomiting. On the other hand, 
Parvin Sajedi et al. (6) concluded in their study that granisetron able to provide the 
benefits without further increasing the risk of respiratory and cardiovascular side effects. 
In this study, they suggested that their limitation was lack of previous studies in 
determining the dose of granisetron in control post anaesthesia shivering.  
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In this study, we examine the minimum dose of intravenous granisetron that can 
prevent post-spinal anaesthesia shivering. If at dose of 10mcg/kg of intravenous 
granisetron can prevent post-spinal anaesthesia shivering, it will mean that there may be 
less side effects, lower treatment cost and at the same time reduction in the incidence 
post-operative nausea and vomiting.  
In conclusion, primary prevention of post-anaesthesia shivering with a cost-
effective drug with minimal side effects should be sought as the current first line therapy 
with IV pethidine is limited by its unfavourable side effects profile.  To the best of our 
knowledge, there is no study in Malaysia that compares two different dosages of 
granisetron versus pethidine in the prevention of post –spinal anaesthesia shivering. 
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2.1 General Objectives 
To determine the effectiveness of IV granisetron 10mcg/kg versus IV granisetron 40 
mcg/kg in the prevention of shivering during spinal anaesthesia for elective orthopaedic 
lower limb surgery with IV pethidine 0.4mg/kg as positive control.  
 
2.2 Specific Objectives 
To compare the incidence of side effects of IV granisetron at two different dosage versus 
pethidine.  
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3.2 ABSTRACT 
 
Background: Post-anaesthesia shivering is physiologically and psychologically stressful 
event. Pethidine, which is commonly recognised as first-line therapy, can have several 
side effects such as sedative effects, nausea and vomiting. Granisetron has been proven 
in various studies for prevention of post-anaesthesia shivering at 40mcg/kg intravenously. 
To date, no study has demonstrated the minimum dose of granisetron to prevent post-
anaesthesia shivering. This study compared two different dosages of intravenous 
granisetron versus pethidine for prevention of post-anaesthesia shivering.  
Methods: This was a prospective, randomized, double-blinded study. A total of 96 
patients with ASA classification I and II, aged between 18 and 65 years old scheduled for 
orthopaedic lower limb surgery under spinal anaesthesia were recruited. Patients were 
randomly allocated to receive either intravenous (IV) granisetron 10mcg/kg (Group 1), 
IV granisetron 40mcg/kg (Group 2) or IV pethidine 0.4mg/kg (Group 3) before an 
intrathecal injection of 15 mg 0.5% hyperbaric bupivacaine. The incidence and severity 
of shivering with side effects of tested drugs were recorded.  
Results: The incidence of shivering associated with spinal anaesthesia in our study was 
not significant different amongst the 3 groups (p = 0.404). However, pethidine was 
associated with sedative effects when compared with granisetron (p <0.001).  
Conclusions: IV granisetron at 10mcg/kg had similar efficacy when compared to both IV 
granisetron 40mcg/kg and IV pethidine 0.4mg/kg in preventing shivering during spinal 
anaesthesia for orthopaedic lower limb surgery. 
Keywords: Spinal Anaesthesia, Shivering, Granisetron, Pethidine, Subarachnoid block, 
5-HT3 
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3.3 INTRODUCTION 
 
Perioperative shivering is commonly encountered in our daily anaesthesia practice 
with estimated incidence varied from 6 -60% after spinal anaesthesia (1).  Shivering is 
physiologically and psychologically stressful to both patients and anaesthetist. Various 
methods are available for prevention post-anaesthesia shivering. Although surface 
warming is a common physical method used for prevention of shivering, it is not 
considered to be as effective as pharmacological methods for this purpose. It is because 
of skin surfaces contributes to only 20% of shivering control (2). Although pethidine is 
one of the drugs used for prevention post-anaesthesia shivering, it is associated with 
bradycardia, nausea and vomiting (10), respiratory depression (10), sedative effects and 
hemodynamic changes. This can be dangerous to elderly patients and those at risk patients. 
Avoidance of one post-anaesthesia complications should not raise up another side effects 
secondary from adding another one medication. Thus, granisetron, a specific 5-HT3 
receptor antagonist, at a dose of 40mcg/kg, has been introduced and found to be effective 
in reducing the incidence of post-anaesthesia shivering in some studies. The mechanism 
of action of granisetron anti-shivering effect could be related to the inhibition of serotonin 
reuptake on the pre-optic anterior hypothalamic region (4). Serotonin (5-
hydroxytryptamine [5-HT]) is a biological amine that has neurotransmitter function in the 
brain and the spinal cord. Studies suggest that the serotoninergic system has a role in the 
control of post-anaesthesia shivering. The 5-HT3 receptor antagonist inhibits the uptake 
of serotonin in the pre-optic anterior hypothalamic region, which influences both heat 
production and heat loss (4). In animal models, direct intraventricular injection of 
serotonin influences body temperature and shivering (2). Granisetron is currently 
registered in the Ministry of Health Drug Formulary, 2013, at a dose of 10-40mcg/kg in 
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children over 2 years old or at a dose of 1 – 3 mg in an adult as intravenous (IV) bolus for 
prevention of nausea and vomiting associated with chemotherapy and radiotherapy. For 
prevention post-anaesthesia shivering, IV granisetron 40 mcg/kg is recommended in most 
studies. A.A. Eldaba and Y.M. Amr in 2012 (8) compared IV granisetron 10mcg/kg 
versus IV normal saline in a group of 80 children age 2 – 5 year old who underwent spinal 
anaesthesia for lower limb surgery. They found that IV granisetron 10mcg/kg was 
effective in preventing post-spinal shivering.  
In this study, we examine the minimum dose of intravenous granisetron that can 
prevent post-spinal anaesthesia shivering. If at dose of 10mcg/kg of intravenous 
granisetron can prevent post-spinal anaesthesia shivering, it will mean that there may be 
less side effects, lower treatment cost and at the same time reduction in the incidence 
post-operative nausea and vomiting. Hence, patients should be offered a drug that can be 
administered at the lowest possible dose with no additional significant side effects. 
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3.4 METHODOLOGY 
 
Research Design 
This was a prospective, randomized, double-blinded study to compare two 
different doses of IV granisetron versus IV pethidine for prevention of shivering post-
spinal anaesthesia with at the same time side effects of both drugs been compared.  
 
Study settings and period 
The study was conducted on patients who were scheduled for orthopaedic lower 
limb surgeries in Hospital Universiti Sains Malaysia (HUSM) and General Hospital 
Penang (GHPP) from September 2015 to August 2016 after ethical approvals were 
obtained (JEPeM code: USM/JEPeM/15020061; NMRR code: NMRR-15-822-24575 
(IIR)).  
 
Patients 
Patients were recruited based on the inclusion and exclusion criteria listed below. 
Inclusion criteria 
i. Age between 18 – 65 years old 
ii. American Society of Anaesthesiology Classification I and II  
iii. BMI 18 – 30 kg/m2 
Exclusion criteria 
i. Pregnancy  
ii. Psychological disorders patient 
iii. Thyroid disorder patient 
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iv. Patient contraindication for spinal anaesthesia 
v. Baseline body temperature outside range of 36.5 – 38 ℃ 
vi. Patient likely to require blood transfusion 
 
Sample size calculation 
Sample size calculation for this study is based on Power and Sample Size 
Calculation Programme (PS version 3.0.43). Previous data showed that median incidence 
of shivering related to neuraxial anaesthesia in the control group was 57.6%. The sample 
size is then calculated using the assumption that the incidence of shivering among the 
patients receiving effective medication pethidine will be 18.2%, in keeping with the 
previous study(6). The power of the study will be 0.8 and type 1 error of 0.05. With 
additional dropout rate of 15%, a total of 96 patients with 32 patients in each group will 
be needed. 
 
Techniques for data collection 
Ethical committee approvals were obtained prior to this study. Patients who 
fulfilled the criteria were explained and written consent obtained during pre-anaesthesia 
assessment. Oral midazolam was given a night prior to the surgery and before sending 
patients to operation theatre. Prior to the induction of anaesthesia, non-invasive blood 
pressure (NIBP), heart rate (HR), oxygen saturation (SPO2), cardiac monitoring and 
baseline body temperature (using infrared ear thermometer) were obtained. All the 
patients were preloaded with 10mls/kg IV warmed crystalloid fluids over 15 minutes prior 
to the spinal anaesthesia. Via computer generated randomization, patients were allocated 
randomly into 3 groups to receive IV granisetron 10 mcg/kg (Group 1, n = 32), IV 
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granisetron 40 mcg/kg (Group 2, n = 32) or IV Pethidine 0.4mg/kg (Group 3, n = 32) in 
a total volume of 5ml over 5 minutes prior to the spinal anaesthesia. The attending 
anaesthesiologist was blinded to the type of drug used in the study. All the patients will 
be positioned for the surgery after spinal anaesthesia was performed at L3-L4 interspaces 
with 3mls of 0.5% hyperbaric bupivacaine. All of them were covered with forced air 
warmer (Bair Hugger) set at temperature 38ºC. All intravenous fluids preheated to 37˚C 
by fluid warming device were given as 2mls/kg/hour. The operating room temperature 
was maintained at 18-22ºC. Incidence and severity of shivering, and body temperature 
were assessed at 10 minutes interval after spinal anaesthesia till 60 minutes post-spinal 
anaesthesia. Blood pressure, heart rate, SPO2, respiratory rate, sedation score, incidence 
of nausea and vomiting were assessed every 2.5-minute interval up to 15 minutes, 
followed by 5-minute interval till 60 minutes post-spinal anaesthesia. At recovery area, 
all the above-mentioned monitoring was assessed and recorded. Shivering was noted by 
attending anaesthesiologist and considered once happened. Shivering was graded using a 
scale similar to that validated by Tsai and Chu(11): 
- Grade 0: no shivering 
- Grade 1: piloerection but no visible shivering 
- Grade 2: muscular activity in only one muscle group 
- Grade 3: muscular activity in more than one muscle group but not 
generalized 
- Grade 4: shivering involving the whole body 
 
Only grade 3 and 4 were considered as severe shivering, and study prophylaxis 
drug was considered as ineffective. IV pethidine 25mg was administered as rescue drug 
for severe shivering. At the same time, close monitoring vital signs were continued with 
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active rewarming physical methods would be reinforced further. Decrease of systolic 
blood pressure (SBP) less than 90 mmHg was treated with iv phenylephrine 100mcg. IV 
atropine 0.5mg bolus was given for heart rate less than 50 beats per minute.  
 
Sedation score was assessed with 5-point scale(12):  
i. Grade 1 : fully awake and orientated 
ii. Grade 2 : drowsy 
iii. Grade 3 : eyes closed but arousable to command 
iv. Grade 4 : eyes closed but arousable to mild physical stimulation 
v. Grade 5 : eyes closed but unarousable to mild physical stimulation 
 
Data was analyzed using Statistical Package for the Social Science (SPSS) 
version 22.0 and were expressed as mean ± SD. The changes of blood pressure, HR and 
temperature were analyzed using analysis of variance (repeated annova) for repeated 
measurements between groups. Incidence of shivering as well as side effects of the 
study drugs were analyzed by Chi-Square test. A p-value less than 0.05 was considered 
statistically significant.  
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3.5 RESULTS 
 
A total of 96 participants were recruited and divided into three different study 
groups with each group 32 patients that received different anaesthetic drug regimens i.e. 
IV Granisetron 10 mcg/kg (Group I), IV Granisetron 40mcg/kg (Group II), and IV 
Pethidine 0.4mg/kg (Group III). One of the patient from group 3 was drop out due to 
failed spinal anaesthesia and converted into general anaesthesia. Overall demographic 
data of study participants are shown in Table 1. The youngest was 18 years old and the 
eldest age was 65 years old. There was no statistically different with regards to age, 
gender, race and weight among 3 groups of patients. Significant different difference was 
found in height of study participants. Nevertheless, the magnitude of changes is small and 
negligible (Table 2). Duration of surgery among three groups of patients were similar.  
 
The changes of the haemodynamic profile (i.e. SBP, PR, RR and SPO2) post-
spinal anaesthesia among study participants were shown in Figures 1 – 4. Although 
changes in the hemodynamic profile were observed among the three different study 
groups, the magnitude of these changes were negligible during clinical practice.  
 
There were changes of tympanic membrane temperature in all three groups post-
spinal anaesthesia when compared with on arrival temperature readings. However, the 
magnitude was small and is clinically irrelevant. There was no significant difference when 
comparison was made amongst the three groups. 
 
Regarding incidence of shivering, no significant differences were observed 
amongst the three groups. The overall shivering incidence in this study group was 8.4%. 
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Although both granisetron group show of higher incidence of shivering when compared 
with pethidine, but that was statistically insignificant. Among the 8 patients who shivered 
post-spinal anaesthesia, none of them still had shivering when they were discharged from 
recovery area.  
 
Overall recorded side effects for the three study groups of study participants are 
shown in Table 3. There were no significant differences in distribution of side effects for 
hypotension, bradycardia, nausea, headache and giddiness among the three different study 
groups. However, significant higher incidence of sedation score ≥2 was observed in 
patients received IV pethidine 0.4mg/kg, compared to the other two groups that received 
IV granisetron (Table 4).  
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3.6 DISCUSSION 
 
This study was done to evaluate the efficacy of preventing post-anaesthesia 
shivering by two different doses granisetron in comparison with pethidine. In this study, 
we found that IV granisetron 10mcg/kg could decrease incidence of post-anaesthesia 
shivering and this was comparable to IV granisetron 40mcg/kg and IV pethidine 0.4mg/kg.  
 
Shivering is one of the common and stressful problems for both patients and 
anaesthetist. This additional burden may cause unpleasant experience in operation theater 
to patients. Several undesirable effects can be a physiological stress. Thus, avoiding 
shivering is essential for better perioperative patient outcome.  
 
However, the precise cause of shivering post-anaesthesia is still not yet fully 
understood. Multiple mechanisms have been suggested to explain its occurrence. It could 
be due to thermoregulatory effects secondary to core hypothermia or possible of unknown 
non-thermoregulatory cause. (13, 14) In our study, we try our best to standardized 
possible factors to avoid added risk for hypothermia by administering prewarmed 
intravenous fluids and by covering patients with forced air warmer. These preventive 
measures were also adopted in other studies. (4, 15) Although preventing hypothermia 
intraoperative is one of the key component in avoiding shivering intraoperative, shivering 
may even happen among normothermic patient. (16) Our findings in this study consistent 
with this theory. The mean core temperature recorded among 3 groups were still within 
normal human core temperature (36.5 to 37.5 ℃ ). (17) We choose to use infrared 
tympanic membrane temperature for monitoring core temperature as this is one of the 
reliable sites which correlates well with core temperature. (4)  
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Regulation of post-anaesthesia shivering by 5-HT3 antagonist has not been fully 
understood. It is postulated the mechanism could be due to its serotonergic pathway (18) 
and its function on thermoregulatory effects in anterior hypothalamus. (19) A number of 
studies has showed granisetron can have similar prevention of post-anaesthesia shivering 
achievement with pethidine.(5, 6, 20, 21) Iqbal et al. (5) reported IV granisetron 40 
mcg/kg was as effective as IV pethidine with no statistically different in preventing 
postoperative shivering. The reported incidence was 17%. When comparing granisetron 
with placebo, Sagir et al. (3) showed that it can significantly reduce post-anaesthesia 
shivering with incidence of shivering as low as 10%.  In our study, the incidence of 
shivering in patients received IV granisetron 40 mcg/kg was 12.5%. 
 
At lower dose of granisetron (10 mcg/kg), we found that it produced similar 
results as IV granisetron 40 mcg/kg. Eldaba & Amr (22) evaluated the efficacy of IV 
granisetron 10 mcg/kg in children who underwent lower limb surgeries and they 
concluded that granisetron was an effective agent to prevent shivering after spinal 
anaesthesia. There were few studies demonstrated lower dose of IV granisetron could 
reduce incidence of shivering post-anaesthesia. Khalifa (23) found that statistically 
significant lesser incidence of shivering in patient receiving 1 mg IV granisetron when 
compared with placebo group. Lower incidence of shivering with premedication IV 
granisetron 1mg was detected in study done by Kasem. (24) As compared to our study, 
this lower incidence could be due to the dose for spinal anaesthesia given by Kasem (24) 
was lower than us. At the sametime, no proper classification guidelines for shivering 
grading been specified in the study by Kasem. We used shivering grading scale similar to 
that validated by Tsai and Chu. (11) 
19 
 
 
In this study, we were unable to demonstrate the benefit of 5-HT3 antagonist on 
the prevention of hypotension and bradycardia post-spinal anaesthesia. Administration of 
IV granisetron had no effect on hemodynamic variables in our study were consistent with 
other studies. (21, 24, 25) Recent published meta-analysis study by Wang et al. (21) 
showed that 5-HT3 antagonist did not show superiority in reducing incidence of 
bradycardia and hypotension. 
 
The usefulness of pethidine for controlling shivering post-anaesthesia could be 
limited by its side effects, such as pruritus, nausea and vomiting, respiratory depression, 
sedated and bradycardia in some studies. (18, 19, 24). Our study was consistent with its 
sedation effects which should raise the caution when used in elderly. Elderly patient may 
not well tolerate pethidine and may cause delirium perioperatively. (26) In year 2004, 
ISMP Canada (26) recommended the limitation use of pethidine due to its adverse effects. 
Thus, it is important to aware that we should not cause another complication because of 
adding another medication for preventing of the initial anaethesia complication.  
 
We recognize that there were confounding factors and limitation in this study. Our 
study involved multiple operators which can contribute bias into this study. At the same 
time, in term of race, Malay form the majority (80%) of study participants though the data 
collection were done both at Kelantan and Penang. This can be explained by Kelantan 
state is predominantly Malay. Although there is still insufficient data to suggest 
correlation between race and post-anaesthesia shivering, further work out is still required 
to rule out this possibility. Moreover, this was the first study comparing two different 
doses of IV granisetron to control post-anaesthesia shivering. Monitoring of core 
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temperature by using infrared tympanic membrane temperature probe may cause bias as 
wax in auditory canal may misleading us the true core temperature. We were unable to 
insert more invasive oesophageal temperature probe or thermistor in pulmonary artery as 
our study subjects were awake.  
 
We hope that there will be more studies will be carried out in future to confirm 
our findings and the ideal agents for prevention of shivering post-anaesthesia. The ideal 
prevention method is still not established. In addition to adding antishivering drug, we 
should try the best possible method to maintain normothermia perioperatively to reduce 
the distressing shivering events.  
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3.8 TABLES AND FIGURES 
 
Table 1 Overall demographic data of study participants 
Variable Mean (SD) 
  
Age, Year 37 (15) 
  
Age Group, n (%)  
 18 – 33, 48 (51) 
 34 – 49 21 (22) 
 50 – 65 26 (27) 
  
Gender, n (%)  
 Male 73 (77) 
 Female 22 (23) 
  
Race, n (%)  
 Malay 76 (80) 
 Chinese 11 (12) 
 Indian 7 (7) 
 Others 1 (1) 
  
Treatment Group  
 IV Granisetron 10 mcg/kg 32 (33.7) 
 IV Granisetron 40mcg/kg 32 (33.7) 
 IV Pethidine 0.4mg/kg 31 (32.6) 
  
Height 166.0 (7.7) 
  
Weight 66.5 (12.4) 
  
  
Duration of surgery, minutes (SD) 110.16 (39.59) 
  
Mean temperature, degree Celsius (SD) 36.8 (0.2) 
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Table 2  Demographic data of study participants according to different study 
groups 
Variable 
IV 
Granisetron 
10 mcg/kg 
(n=32) 
IV 
Granisetron 
40 mcg/kg 
(n=32) 
IV 
Pethidine 
0.4mg/kg 
(n=31) 
P value 
     
Age, Year 38 (14) 34 (15) 38 (15) 0.406a 
     
Age Group, n (%)     
 18 – 33, 14 (44) 19 (59) 15 (48) 0.534b 
 34 – 49 10 (31) 5 (16) 6 (19)  
 50 – 65 8 (25) 8 (25) 10 (33)  
     
Gender, n (%)     
 Male 27 (84) 21 (66) 25 (81) 0.171b 
 Female 5 (16) 11 (34) 6 (19)  
     
Race, n (%)     
 Malay 22 (69) 26 (81) 29 (91) 0.214b 
 Chinese 4 (13) 4 (13) 3 (9)  
 Indian 5 (16) 2 (6) -  
 Others 1 (3) - -  
     
Height 168.6 (7.5) 164.5 (8.7) 164.8 (6.1) <0.001a* 
     
Weight 73.9 (10.9) 61.7 (12.1) 63.9 (10.8) 0.060a 
     
Duration of surgery, 
minutes (SD) 
119.84 (41.44) 108.75 (40.62) 
101.61 
(35.41) 
0.184 
     
Mean temperature, 
degree Celsius (SD) 
36.9 (0.2) 36.9 (0.2) 36.9 (0.2) 0.808 
     
Note: aOne way ANOVA; bChi-square test for homogeneity, statistically significant at 
p<0.05 
 
 
 
 
 
 
